Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Moderna, Inc.NASDAQ: MRNA

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $127M rose 1.6% year over year, ahead of the -25.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.

Context

  • Stock-based compensation amounted to 24.8% of revenue in FY2025, up 11.4 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.6% holds above the trailing-twelve-month pace of -25.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$127M+5.8% QoQ
Last fiscal yearDec 2025
$483M+12.6% YoY
LTMSep 2026
$351M-25.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year+12.6%——
3-year CAGR+28.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
483M USD
Year-over-year change
+12.6%
4-year CAGR
+35.8%

Stock-Based Compensation vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.9% is the 4th highest of 7, against a peer median of -6.9%.
  • Stock-based compensation amounts to 13.9% of revenue for MRNA, versus a peer median of 1.5%.
MRNA Competitors
Stock-Based Compensation for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$947M USD+14.9%-2.9%1.5%
MRNAModerna, Inc.LTM Sep 2026$351M USD-25.9%+28.8%13.9%
PCVXVaxcyte, Inc.LTM Jun 2026$188.47M USD+66.5%+80.4%—
VIRVir Biotechnology, Inc.LTM Mar 2026$35.01M USD+17.1%-21.7%53.5%
NVAXNovavax, Inc.LTM Mar 2026$33.45M USD-28.6%-34.9%5.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M USD-33.2%-6.0%50.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M USD-44.1%-45.0%—
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding MRNA) —-6.9%-13.8%1.5%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Depreciation & Amortization232M348M621M189M215M
Deferred Income Tax(318M)(559M)828M00
Stock-Based Compensation142M226M305M429M483M
Change in Working Capital1.31B(3.46B)(139M)(78M)254M
Accounts Receivables(1.78B)1.79B493M534M156M
Inventory(1.39B)492M747M83M(34M)
Accounts Payables204M240M13M(69M)(92M)
Other Working Capital4.28B(5.98B)(1.39B)(626M)224M
Other Non-Cash Items54M59M(19M)17M(3M)
Operating Cash Flow13.62B4.98B(3.12B)(3B)(1.87B)
Capital Expenditures(284M)(400M)(707M)(1.05B)(192M)
Acquisitions (Net)00(85M)00
Purchases of Investments(12.65B)(11.44B)(3.78B)(6.53B)(5.77B)
Sales of Investments4.44B6.7B8.78B9.53B7.92B
Other Investing Activities(30M)(40M)00(10M)
Investing Cash Flow(8.52B)(5.18B)4.21B1.95B1.95B
Debt Repayment(140M)(184M)(270M)(10M)539M
Common Stock Issued124M65M46M66M35M
Common Stock Repurchased(857M)(3.33B)(1.15B)00
Dividends Paid00000
Other Financing Activities000019M
Financing Cash Flow(873M)(3.45B)(1.38B)56M593M
Effect of Forex Changes00002M
Net Change in Cash4.22B(3.64B)(289M)(999M)668M
Free Cash Flow13.34B4.58B(3.83B)(4.06B)(2.07B)

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.